Cefodort-CV Tablets
Cefpodoxime Proxetil 200 mg + Potassium Clavulanate 125 mg
Cefodort-CV Tablets
(Cefpodoxime Proxetil 200 mg + Potassium Clavulanate 125 mg)
Description:
Cefodort-CV Tablets combine Cefpodoxime Proxetil 200 mg, a third-generation cephalosporin antibiotic, with Potassium Clavulanate 125 mg, a beta-lactamase inhibitor, to provide broad-spectrum antibacterial coverage. This powerful combination is designed to treat infections caused by both resistant and non-resistant bacteria. Cefpodoxime eliminates the bacteria by inhibiting their cell wall synthesis, while Clavulanate enhances its effectiveness by preventing bacterial resistance, ensuring optimal outcomes in the treatment of severe or resistant infections.
Key Ingredients:
- Cefpodoxime Proxetil 200 mg: Cefpodoxime is a third-generation cephalosporin antibiotic known for its strong activity against both gram-positive and gram-negative bacteria. It works by inhibiting bacterial cell wall synthesis, causing bacterial death. It is highly effective in treating respiratory, urinary, and skin infections, as well as sexually transmitted infections.
- Potassium Clavulanate 125 mg: Clavulanate is a beta-lactamase inhibitor that prevents bacteria from inactivating Cefpodoxime through the production of beta-lactamase enzymes. By neutralizing this resistance mechanism, Clavulanate enhances the efficacy of Cefpodoxime, making it effective against beta-lactamase-producing bacteria.
Indications:
- Upper and lower respiratory tract infections (e.g., pneumonia, sinusitis, bronchitis)
- Urinary tract infections (e.g., cystitis, pyelonephritis)
- Skin and soft tissue infections (e.g., cellulitis, wound infections)
- Complicated infections caused by beta-lactamase-producing bacteria
- Severe bacterial infections requiring broad-spectrum coverage
Benefits of Cefodort-CV Tablets:
- Combines Cefpodoxime’s broad-spectrum antibacterial action with Clavulanate’s ability to overcome bacterial resistance, providing enhanced efficacy.
- Effective against beta-lactamase-producing bacteria that are resistant to other antibiotics, making it ideal for treating complicated infections.
- Targets a wide range of infections, including respiratory, urinary, and skin infections, with reliable results.
- Convenient oral dosing and excellent absorption ensure effective therapeutic levels in the body for fast and efficient bacterial eradication.
- Provides a robust treatment option for infections that may not respond to standard antibiotics, ensuring greater treatment success.
Dosage:
As prescribed by the healthcare professional, typically one tablet every 12 hours, depending on the severity and type of infection. The treatment duration may vary but is generally 7-14 days based on the infection being treated.
Precautions:
- Avoid use in patients with known hypersensitivity to cephalosporins, penicillin, or beta-lactamase inhibitors.
- Use with caution in patients with kidney or liver impairment; dose adjustments may be necessary.
- Prolonged use may result in the overgrowth of non-susceptible organisms, including fungi.
- Pregnant and breastfeeding women should consult their healthcare provider before use.
- Complete the prescribed course to prevent bacterial resistance and ensure effective treatment.
Conclusion:
Cefodort-CV Tablets offer a powerful, dual-action solution for the treatment of a wide range of bacterial infections, especially those caused by beta-lactamase-producing bacteria. With the combination of Cefpodoxime Proxetil 200 mg and Potassium Clavulanate 125 mg, Cefodort-CV provides enhanced antibacterial activity, ensuring reliable results in treating complex respiratory, urinary, and skin infections. This combination therapy is trusted for its ability to overcome bacterial resistance and deliver optimal outcomes for patients suffering from severe or complicated infections.